Ibu-Lysin

Ibuprofen D,l-Lysinate, the active ingredient in Ibu-Lysin, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for oral use. It provides analgesic, antipyretic and anti‑inflammatory effects for mild to moderate pain in adults.

GNH USA supplies Ibu-Lysin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibu-Lysin (ibuprofen D,l‑lysinate) is used to manage conditions involving pain, fever and inflammation.

- Mild to moderate pain: reduces pain perception and improves functional ability. - Fever: lowers elevated body temperature through prostaglandin inhibition. - Arthritis: alleviates inflammatory joint pain and swelling.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia or abdominal discomfort. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Skin rash: mild erythematous eruption.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulcer perforation. - Acute renal impairment, especially in volume‑depleted patients. - Severe allergic reactions such as anaphylaxis or angioedema. - Hepatotoxicity: elevated liver enzymes or jaundice. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately. - Gastro‑intestinal risk: assess history of ulcers or bleeding and use gastro‑protective agents if needed. - Renal function: monitor serum creatinine in patients with pre‑existing kidney disease. - Pregnancy: avoid use in the third trimester due to fetal cardiovascular risks. - Concomitant anticoagulants: increase bleeding risk; use caution. - Hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ibu-Lysin may interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Corticosteroids: increased risk of ulceration. - ACE inhibitors or ARBs: potential for reduced renal perfusion. - Lithium: elevated lithium serum concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate renal impairment. - Methotrexate: reduced clearance leading to toxicity.